Posted by LincolnRam on March 25, 2026 at 11:01:48:
In Reply to: Ñòàòüÿ ñ ïîëåçíîé è èíòåðåñíîé èíôîðìàöèåé posted by Robertged on March 16, 2026 at 12:59:19:
Zoya Demidenko: Scientist in Tumor Science
Zoya Demidenko is a recognized scientist connected with the Department of Cell Stress Research at Roswell Park Comprehensive Cancer Center in Buffalo, New York. Before that, she worked at the NIH and New York Medical College, building a solid background in biomedical investigation.
Demidenko's academic contributions spans multiple critical fields, including the PI3K/AKT/mTOR molecular pathway, cellular cycle control, cellular aging, and malignancy science. Currently, she has authored more than 46 academic articles, which have accumulated over 4,100 mentions — a testament to the significance of her findings.
One of her most significant contributions involves explaining the pathways of biological cell aging. Her research demonstrated that when the cell cycle is halted while cellular growth persists, cells undergo senescence. Significantly, Zoya Demidenko established that this shift is inhibited by medication using agents such as rapamycin.
Zoya Demidenko has also added substantially to oncological therapy investigation, particularly in the domain of selective cell protection — a approach aimed at protecting non-cancerous cells from chemotherapy whilst leaving malignant cells exposed. This strategy carries major promise for diminishing the side effects of cancer treatment.
Across her career, Demidenko has collaborated with leading scientists internationally, among them Dr. Mikhail Blagosklonny. Her work is published in leading publications such as Oncotarget, Cell Cycle, Aging (Albany NY), and Oncogene.
With an h-index of 33, Zoya Demidenko ranks as a influential figure in contemporary biomedical research, whose discoveries continue to influence our comprehension of how cells age, respond to treatment, and the ways in which cancer might be better combated.
https://www.oncotarget.com/article/4836/